Threats, moves, and gaps — the forward view

Convert remaining DME-only states to pharmacy fulfillment, removing the #1 T2D conversion friction.

Push co-prescription with GLP-1s and pursue formulary bundles with the top 3 PBMs to lock in T2D pull-through.

Large RWE cohort (>10K T2D pts) showing -1.0% A1C and TIR uplift cements payer narrative.

Second CGM partner reduces Dexcom dependency and opens lower-cost T2D bundles via Abbott pharmacy footprint.

OTA SmartAdjust update tuned for higher TDD and meal patterns common in T2D, reducing alarms.

First major DTC push (TV + digital) framing Omnipod as the easy step up from MDI for T2D.

Replicate US T2D label win in MDR-regulated markets; first MDR submissions land within 9 months.

Bluetooth-direct iteration removes the controller dependency for T2D users, simplifying onboarding.

Per-member-per-month pricing tied to A1C outcomes — a defensive moat against price competition.

Bolt-on a coaching SaaS to own the T2D engagement layer and capture RPM CPT codes.

Control-IQ+ pivotal hit primary endpoint; PMA supplement filed for Mobi T2D within two quarters.

Phone-first bolus + remote update parity vs Omnipod 5 closes the UX gap on smartphone control.

Mobi MDR clearance lands; commercial launch in Germany + UK first, then France/Italy/Spain.

Multi-CGM strategy adds Abbott to Dexcom, lowering total cost of care for T2D bundles.

T2D ASP pressure forces Tandem into a list-price reduction or rebate restructure on Mobi.

Cost-out of 8–12% headcount to free $40–60M for T2D commercial build.

Tandem ships an integrated population dashboard for endo clinics, improving stickiness.

Patch acquisition matures into 510(k)/PMA filing, giving Tandem a tubeless answer to Omnipod.

After adult T2D label, Tandem files for pediatric T2D — first mover in adolescent T2D AID.

Compressed market cap + clean tubeless asset (Sigi) makes Tandem an attractive bolt-on.

Simplera Sync ships to US distributors and unlocks integrated 780G + CGM bundle pricing.

PMA supplement converts; 780G becomes the first traditional tubed pump with explicit T2D indication.

780G T2D label in EU + Japan reimbursement wins drive disproportionate ex-US growth.

Software update tunes auto-correction thresholds for higher TDD and lower hypo risk in T2D.

Simplera positioned as GLP-1 companion CGM, separate from pump funnel — opens broader T2D TAM.

Vertically integrated remote titration platform leveraging CMS RPM/RTM codes for T2D AID.

To capture pre-pump T2D patients, MDT picks up Bigfoot, Embecta digital, or a Companion-style asset.

Bundled pump + CGM + supplies + support priced PMPM for self-insured employers.

Residual MDR-era quality system risk surfaces a Class II recall, distracting commercial focus.

Following long-standing investor pressure, MDT formally separates Diabetes into a tracking stock or spin-co.

13-week primary endpoint readout drives 510(k)/PMA push and a phased commercial rollout.

Following pivotal data, Beta Bionics scales sales force into 30 states with focus on long-term care.

Cash burn outpaces commercial ramp; raise $80–120M to fund T2D launch through 2027.

iLet adds Libre 3+ as second CGM partner, broadening payer flexibility for T2D.

iLet's simplicity wins a meaningful VA T2D AID contract — a credibility booster and steady revenue base.

Health Canada + UK MHRA filings convert; commercial entry into single-payer markets begins.

Beta Bionics initiates pediatric T2D study leveraging adaptive dosing simplicity advantage.

Strong T2D readout + small float = attractive bolt-on for a pharma seeking AID anchor for GLP-1 strategy.

If T2D pivotal misses or commercial uptake lags, Beta cuts 15–20% to extend runway.

Glucagon partner secured; dual-hormone iLet variant re-enters clinical pipeline.

Hiring pattern (VP Payer, Dir HEOR) signals Q1–Q2 ramp; first regional Blues contract within 9 months.

Sequel uses creator partnerships and DTC to leapfrog brand awareness vs entrenched pumps.

Open-source community + Sequel ship a T2D titration variant tuned for higher TDD and meal patterns.

Following T1 launch traction, Sequel files PMA supplement leveraging real-world T2D off-label data.

Sequel ships first-of-kind Apple Watch bolus control, a marketing differentiator with younger T2D users.

NH manufacturing scale-up hits yield issues, capping shipments below demand for 1–2 quarters.

Sequel locks an exclusive co-promote with one CGM maker for T2D, simplifying go-to-market.

Burn outpaces commercial ramp; bridge financing hints at receptivity to a strategic buyer in 12–18 months.

Sequel forks Loop into a proprietary commercial branch to control T2D-specific tuning and update cadence.

Tubeless-adjacent + Loop algorithm + small cap = attractive bolt-on for a strategic seeking AID entry.